Compare Cardiovascular Benefits of SGLT2 Inhibitors for Type 2 Diabetes
January 2019
SGLT2 inhibitors (Invokana, etc) are in the spotlight again.
Reps will say Invokana (canagliflozin) is now approved to reduce risk of CV events in adults with type 2 diabetes and CV disease...while Jardiance (empagliflozin) is only approved to reduce CV death.
But Invokana's approval is based on NONsignificant reductions in CV death, MI, or stroke...lumped into one significant composite outcome.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote